Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system

Journal of Neuro-Oncology

Volumn 121, Issue 2, 2015, Pages 289-296

  Akhter, Ariz ^a   Masir, Noraidah ^b   Elyamany, Ghaleb ^c   Phang, Kean Chang ^b   Mahe, Etienne ^a   Al Zahrani, Ali Matar ^c   Shabani Rad, Meer Taher ^a   Stewart, Douglas Allan ^d   Mansoor, Adnan ^a,e  

^a CALGARY LABORATORY SERVICES   (Canada)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c Prince Sultan Military Medical City   (Saudi Arabia)

^d UNIVERSITY OF CALGARY   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

Author keywords

B cell receptor; MYD88 mutations; nCounter analysis; Primary central nervous system lymphoma; Toll like receptor

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD79A ANTIGEN; CD79B ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 10; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; B LYMPHOCYTE; BCL10 GENE; BLNK GENE; CARD11 GENE; CD79A GENE; CD79B GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYN GENE; MALT1 GENE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; TOLL LIKE RECEPTOR 4 GENE; TOLL LIKE RECEPTOR 5 GENE; TOLL LIKE RECEPTOR 7 GENE; TOLL LIKE RECEPTOR 9 GENE; UPREGULATION; CENTRAL NERVOUS SYSTEM TUMOR; GENE EXPRESSION REGULATION; METABOLISM;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; RECEPTORS, ANTIGEN, B-CELL; TOLL-LIKE RECEPTORS;

EID: 84925466917     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1655-3     Document Type: Article

References (37)

1. Kluin PDM, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 240–241
2. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418. doi:10.1038/bjc.2011.357
3. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036–1047
4. Norden AD, Drappatz J, Wen PY, Claus EB (2011) Survival among patients with primary central nervous system lymphoma, 1973–2004. J Neurooncol 101:487–493. doi:10.1007/s11060-010-0269-7
5. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM (2002) Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosom Cancer 35:38–48. doi:10.1002/gcc.10093
6. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723. doi:10.1182/blood-2005-03-0897
7. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O’Neill BP, Lai WR, Park PJ, McKinney M (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111:3200–3210. doi:10.1182/blood-2007-10-119099
8. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, Schuuring E, Kluin P (2008) Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 216:209–217. doi:10.1002/path.2399
9. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032. doi:10.1182/blood-2011-01-293050
10. Deckert M, Engert A, Bruck W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Kuppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, DeAngelis LM (2011) Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 25:1797–1807. doi:10.1038/leu.2011.169
11. Montesinos-Rongen M, Schafer E, Siebert R, Deckert M (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 124:905–906. doi:10.1007/s00401-012-1064-7
12. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 122:791–792
13. O’Neill LA (2002) Signal transduction pathways activated by the IL-1 receptor/Toll-like receptor superfamily. Curr Top Microbiol Immunol 270:47–61
14. Li X, Jiang S, Tapping RI (2010) Toll-like receptor signaling in cell proliferation and survival. Cytokine 49:1–9. doi:10.1016/j.cyto.2009.08.010
15. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801. doi:10.1016/j.cell.2006.02.015
16. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511. doi:10.1038/nri1391
17. Schmidt C (2006) Immune system’s Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst 98:574–575. doi:10.1093/jnci/djj198
18. Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Siemer D, Zuhlke-Jenisch R, Pels H, Jurgens A, Schlegel U, Schmidt-Wolf IG, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Kuppers R, Siebert R, Deckert M (2007) Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 66:230–237. doi:10.1097/01.jnen.0000248553.45456.96
19. Wolska A, Lech-Maranda E, Robak T (2009) Toll-like receptors and their role in hematologic malignancies. Curr Mol Med 9:324–335
20. Zhao WJ, Xi LY, Ma L (2008) Effect of Penicillium marneffei on TLR-2, TLR-4, and Dectin-1 expression and TNF-alpha production in macrophage. Nan Fang Yi Ke Da Xue Xue Bao 28:37–40
21. Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, Li Y, Yang J, Cai Z, Yi Q (2013) Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer 119:782–791. doi:10.1002/cncr.27792
22. Huang WT, Weng SW, Huang CC, Lin HC, Tsai PC, Chuang JH (2012) Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFkappaB pathway. APMIS 120:872–881. doi:10.1111/j.1600-0463.2012.02915.x
23. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G (2008) Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112:2205–2213. doi:10.1182/blood-2008-02-140673
24. Kulkarni MM (2011) Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol Chapter 25(Unit25B):10. doi:10.1002/0471142727.mb25b10s94
25. Wang JQ, Jeelall YS, Ferguson LL, Horikawa K (2014) Toll-like receptors and cancer: MYD88 mutation and inflammation. Front Immunol 5:367. doi:10.3389/fimmu.2014.00367
26. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquieres H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res 18:5203–5211. doi:10.1158/1078-0432.ccr-12-0845
27. Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H, Peschel C (2000) Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 28:558–568
28. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G (2005) B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res Off J Am Assoc Cancer Res 11:1490–1499. doi:10.1158/1078-0432.CCR-04-1890
29. Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L (2014) Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol 7:57. doi:10.1186/s13045-014-0057-5
30. Ben Abdelwahed R, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, Sautes-Fridman C, Mahjoub A, Fisson S (2013) Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res CR 32:18. doi:10.1186/1756-9966-32-18
31. Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST (2014) High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 28:719–720. doi:10.1038/leu.2013.348
32. Brunn A, Utermohlen O, Sanchez-Ruiz M, Montesinos-Rongen M, Blau T, Schluter D, Deckert M (2010) Dual role of B cells with accelerated onset but reduced disease activity in P0(1)(0)(6)(-)(1)(2)(5)-induced experimental autoimmune neuritis of IgH (0)(/)(0) mice. Acta Neuropathol 120:667–681. doi:10.1007/s00401-010-0724-8
33. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88–92. doi:10.1038/nature08638
34. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115–119. doi:10.1038/nature09671
35. Deckert M, Montesinos-Rongen M, Brunn A, Siebert R (2014) Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol 127:175–188. doi:10.1007/s00401-013-1202-x
36. Ye H, Gong L, Liu H, Hamoudi RA, Shirali S, Ho L, Chott A, Streubel B, Siebert R, Gesk S, Martin-Subero JI, Radford JA, Banerjee S, Nicholson AG, Ranaldi R, Remstein ED, Gao Z, Zheng J, Isaacson PG, Dogan A, Du MQ (2005) MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 205:293–301. doi:10.1002/path.1715
37. Schwindt H, Vater I, Kreuz M, Montesinos-Rongen M, Brunn A, Richter J, Gesk S, Ammerpohl O, Wiestler OD, Hasenclever D, Deckert M, Siebert R (2009) Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 23:1875–1884. doi:10.1038/leu.2009.120